

Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells

ZHIHUA LI^{1,3*}, NA WANG^{1,4*}, JIEYU FANG², JINTAO HUANG¹, FEN TIAN¹, CHAOHONG LI¹ and FUKANG XIE¹

¹Department of Histology and Embryology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong;

²Department of Anesthesiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, P.R. China

Received December 2, 2011; Accepted February 28, 2012

DOI: 10.3892/or.2012.1728

Abstract. This study was designed to investigate the role of protein kinase C (PKC) and extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in tamoxifen (TAM)-induced apoptosis and drug resistance in human breast cancer cells. Drug-sensitive, or estrogen receptor (ER)-positive human breast carcinoma cells (MCF-7) and the multi-drug-resistant variant (ER-negative) MCF-7/ADR cells were treated with doses of TAM for various periods of time. Cell viability and apoptosis were assessed using cell counting, DNA fragmentation and flow cytometric analysis. We found that TAM administration caused a significant increase in apoptosis of MCF-7 cells but not MCF-7/ADR cells. Western blot analysis revealed enhanced expression of PKC δ but decreased expression of PKC α in ER-positive MCF-7 cells; while ER-negative MCF-7/ADR cells had decreased levels of PKC δ and increased levels of PKC α . Interestingly, we observed that in MCF-7 cells, TAM stimulated apoptosis by promoting rapid activation of PKC δ , antagonizing downstream signaling of ERK phosphorylation; while in MCF-7/ADR cells, TAM upregulated

PKC α , which promoted ERK phosphorylation. These results suggest that PKC δ enhances apoptosis in TAM-treated MCF-7 cells by antagonizing ERK phosphorylation; while the PKC α pathway plays an important role in TAM-induced drug resistance by activating ERK signaling in MCF-7/ADR cells. The combination of TAM with PKC α and ERK inhibitors could promote TAM-induced apoptosis in breast cancer cells.

Introduction

Breast cancer is a common malignancy in females and the second cause of death from cancer in women today (1). Treatment for breast cancer includes surgery, chemotherapy, radiotherapy and endocrine therapy. Tamoxifen (TAM), an antagonist of the estrogen receptor (ER), is a selective ER modulator (SERM). TAM is a front-line endocrine therapeutic drug for ER-positive breast cancers. Results from TAM therapy showed a 40-50% reduction in the risk of cancer recurrence and cancer mortality (2). Recently, TAM has been demonstrated to be effective for some ER-negative breast cancers, as well as other types of cancers, including gliomas. These data suggest that TAM may also be implicated in ER-independent antitumor mechanisms (3,4). Of note, some advanced breast cancers that initially respond well to TAM eventually become refractory to treatment (5-9). Thus, the traditional mechanism of TAM action through the ER is challenged, and other non-canonical pathways need to be explored.

Protein kinase C (PKC), a family of serine/threonine kinases, is involved in many important cellular functions, including cell proliferation, migration, differentiation, and apoptosis (10-12). Twelve PKC isoforms have been discovered in various cell types, including conventional PKCs (cPKC α , β I/ β II and γ), novel PKCs (nPKC δ , ϵ , η), and atypical PKCs (aPKC ζ) (13,14). The expression of PKC α , δ , ϵ , η , γ , μ , and ζ has been detected in MCF-7 cells (15,16); PKC α is a marker for anti-estrogen resistance and is involved in the growth of TAM-resistant human breast cancer cells (17,18). Overexpression of PKC α stimulates the proliferation of MCF-7 cells and C6 glioma cells (14,19). PKC δ controls cellular proliferation, differentiation, migration and apoptosis in various cell types (13,21,22), representing the predominant isoform expressed in MCF-7 cells (20). Studies of PKC δ in estrogen-responsive tissues have been contradictory. PKC δ increased proliferative and survival capacities in an immortal-

Correspondence to: Professor Fukang Xie, Department of Histology and Embryology, Zhongshan School of Medicine, Sun Yat-Sen University, 74 Zhongshan Second Avenue, Guangzhou, Guangdong 510080, P.R. China
E-mail: frankxie200@yahoo.com

Present addresses: ³The Third Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong 510150; Key Laboratory for Major Obstetric Diseases of Guangdong Province, Guangzhou; ⁴State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen (Zhongshan) University (East Campus), Guangzhou, P.R. China

*Contributed equally

Abbreviations: TAM, tamoxifen; ER, estrogen receptor; SERM, selective estrogen receptor modulator; ERK1/2, extracellular signal-regulated kinase 1/2; PKC, protein kinase C; MAPKs, mitogen-activated protein kinases; FBS, fetal bovine serum; EDTA, ethylenediamine tetraacetic acid; SDS, sodium dodecyl sulfate; PBS, phosphate-buffered saline; DMSO, dimethyl sulfoxide; PI, propidium iodide

Key words: MCF-7, MCF-7/ADR, apoptosis, drug resistance, tamoxifen, protein kinase C, extracellular signal-regulated kinase

ized mammary cell line (23). Estrogen has been reported to stimulate the expression of PKC δ in the corpus luteum (24), but to downregulate the expression of PKC δ in MCF-7 cells (20). A small molecule PKC δ inhibitor or a dominant-negative PKC δ mutant impaired phorbol ester-induced cell arrest in the G1 phase in SKRB-3 breast cancer cells (25). Alternatively, some studies have suggested that PKC δ could act as a positive regulator of growth in tumor-derived mammary cells, potentially through activating the mitogenic Ras/extracellular signal-regulated kinase 1/2 (ERK1/2) pathway (26,27). A pro-survival role for PKC δ in breast cancer cells has also been reported (22,28).

The mitogen-activated protein kinase (MAPK) superfamily consists of four major sets of kinases: the extracellular-receptor kinases (ERK), c-jun N-terminal or stress-activated protein kinases (JNK/SAPK), ERK5/big MAP kinase 1 (BMK1), and the p38 protein kinases (29). Growth factor-regulated gene transcription and cell proliferation are blocked in mammalian cells when MAPK activity is inhibited (30-32), indicating that MAPKs are necessary for cell growth. Inhibition of ERK signaling using a MEK inhibitor, PD98059, induced apoptosis in MCF-7 cells (33,34). ERK activation was inversely correlated with apoptosis (35,36). Activation of ERK by TAM has previously been shown in HeLa cells (37) and human endometrial cancer cells (38). Recently, TAM was shown to activate ERK in ER-positive MCF-7 and T47D cells but not in ER-negative MDA-MB-231 cells (39). Katayama *et al* (40) suggested that blockade of the MEK-ERK-RSK pathway suppressed cell surface P-glycoprotein expression by promoting its degradation, leading to decreased multidrug resistance (MDR).

Drug resistance is a major clinical limitation for the successful management of breast cancers (42-45). In the present study, we investigated the mechanisms of TAM-induced apoptosis and drug resistance using MCF-7 cells and its multidrug-resistant variant, MCF-7/ADR cells.

Materials and methods

Reagents. RPMI-1640 and phenol red-free RPMI-1640 were purchased from Gibco-BRL (Grand Island, NY, USA). TAM, rottlerin, and PD98086 were obtained from Sigma-Aldrich (St. Louis, MO), dissolved in dimethyl sulfoxide (DMSO) at 10 mM and stored at -20°C. Gö6976 (Calbiochem, San Diego, CA, USA) was dissolved in DMSO at 1 mM and stored at -20°C. Rabbit polyclonal antibodies specific for phospho-PKC α , PKC α , PKC δ , ERK, and β -actin and a mouse monoclonal antibody specific for phospho-ERK were obtained from Cell Signaling Technology (Beverly, MA, USA); the rabbit polyclonal phospho-PKC δ antibody was from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA); and HRP-conjugated secondary antibodies (anti-mouse and anti-rabbit) were from QED, Biovision, Inc. (Hercules, CA, USA). The enhanced chemiluminescence (ECL) kit was purchased from GE Healthcare (USA).

Cell lines and cell cultures. Human breast carcinoma MCF-7 cells and their multidrug resistant variant, MCF-7/ADR cells, were kindly provided by Professor Wenlin Huang (Sun Yat-Sen University, China). The cells were maintained in RPMI-1640 supplemented with 10% fetal bovine serum (FBS), 100 U/ml

of penicillin, and 100 μ g/ml of streptomycin under standard incubation conditions (humidified atmosphere, 95% air, 5% CO₂, 37°C). Cells were passaged every 3 days at a ratio of 1:3 using 0.125% trypsin-0.02% EDTA. For experiments, cells in the third to fourth passage were used. Cells of 5x10⁵/90-mm dish or 10⁵ cells/60-mm dish were cultured in phenol red-free RPMI-1640 supplemented with 10% dextran-coated charcoal (DCC)-FBS according to the protocol of Migliaccio *et al* (46). Following 24 h culture in estrogen-depleted medium, the cells were starved overnight with phenol red-free RPMI-1640 containing 1% DCC-FBS, followed by additions of TAM, rottlerin, Gö6976 or PD98059 at the indicated concentrations. After washing with phosphate-buffered saline (PBS), the cells were collected at the time points indicated.

Cell death analysis. To evaluate the effects of TAM on cancer cell death, cells were plated at a density of 5x10⁵ cells/ml in 60-mm cell culture plates. Following starvation with phenol red-free RPMI-1640 containing 1% DCC-FCS for 24 h, cells were treated with various concentrations (1, 5, 10 or 20 μ M) of TAM at the indicated time periods (1, 3, 6, 12 and 24 h). Thereafter, cells were trypsinized with trypsin-EDTA, stained with trypan blue solution (0.04% w/v), and counted using a hemocytometer. The number of dead or live cells was calculated in each sample, and vehicle controls (0.1% DMSO) were included in each experiment. Each experiment was performed in triplicate.

Detection of apoptotic cells. MCF-7 and MCF-7/ADR cells were grown in 6-well plates at a density of 10,000/well. After treatment with 10 μ M of TAM for 24 h, the cells were fixed in 4% paraformaldehyde for 15 min at room temperature, permeabilized with 0.1% Triton X-100 (Sigma-Aldrich) for 30 min, rinsed with PBS and incubated for 5 min at room temperature with 0.01% DAPI stain (Sigma-Aldrich). Excessive stain was removed by washing the cells with PBS. Nuclei were visualized using a Leica fluorescence microscope. The cells with condensed and/or fragmented nuclei were scored as apoptotic cells.

DNA fragmentation (DNA ladders). To confirm TAM-induced apoptosis, DNA fragmentation was performed in TAM-treated cells as previously described (47). In brief, cells that were treated with TAM for different periods of time were collected and digested in 500 μ l of lysis buffer (10 mM Tris, pH 7.5; 25 mM EDTA; 1% SDS; 100 mM NaCl) for 15 min at room temperature. Lysed cells were then treated with 1 mg/ml of proteinase K (final concentration 100 μ g/ml), and incubated at 56°C for 30 min. DNA was extracted twice with phenol/chloroform/isoamyl alcohol (25:24:1) and chloroform prior to 1.5% agarose electrophoresis. DNA ladders in the gel were detected using GoldView staining (SBS Genetech, China) under UV illumination.

Quantification of apoptosis by flow cytometry. Cells were treated with 5, 10 or 20 μ M of TAM or 0.1% DMSO as a control for 24 h. The cells were then harvested using trypsin-EDTA and were fixed in 70% cold ethanol overnight. The cells were subsequently treated with propidium iodide (50 mg/ml) and RNase (20 mg/ml) for 15 min and analyzed using a flow cytometer (Beckman Coulter) equipped with an air-cooled argon ion laser emitting at a wavelength of 488 nm at 15 mW.




Figure 1. Time course of TAM-induced cell death in breast cancer cells. MCF-7 and MCF-7/ADR cells were treated with 5-20 mM TAM or vehicle control (VC, 0.1% DMSO) for 1, 3, 6, 12 or 24 h followed by staining with trypan blue. Numbers of dead and live cells were counted using a hemocytometer. (A) Cell death curve for MCF-7 cells; (B) cell death curve for MCF-7/ADR cells. Data are the percentage of cell death (mean \pm SD, n=3). *P<0.05 compared to vehicle control.

DNA histograms were assessed using the Beckman Coulter cytometry software from a minimum of 10,000 events/sample. To detect the effect of signaling inhibitors, cells were pretreated with 100 nM of Gö6976, 10 μ M of rottlerin, or 20 μ M of PD98059 for 1 h prior to treatment with or without 20 μ M TAM for 24 h and harvested for flow cytometric analysis of apoptosis. All experiments were performed in triplicate.

Western blot analysis. Western blot analyses were performed as previously described (48). In brief, protein extracts were obtained by lysing 5×10^6 cells in buffer A (20 mM HEPES, pH 7.4, 2 mM EDTA, 50 mM β -glycerophosphate, 1 mM dithiothreitol, 1 mM Na_3VO_4 , 1% Triton, 10% glycerol) supplemented with protease inhibitors (4%) for 15 min on ice followed by sonication for 10 sec. Protein concentration was determined using the Bio-Rad DC protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). Samples (60 μ g) were denatured for 10 min in boiling water, followed by electrophoresis on 12% SDS-polyacrylamide gels and transferred onto nitrocellulose membranes (Pall Corporation, Ann Arbor, MI, USA) using electroblotting. Membranes were probed with antibodies as indicated (non-specific binding was blocked by incubation in TBS with 5% non-fat dry milk), followed by incubation with HRP-conjugated rabbit or mouse secondary antibodies. Detection was performed using enhanced chemiluminescence (Amersham) on Hyperfilm (Fuji, Japan) according to the manufacturer's instructions. The same blots were subsequently stripped and re-blotted with corresponding pan antibodies, and membranes were re-probed with a β -actin antibody as the loading control. For quantification, band intensities were quantified using GeneSnap (SynGene, Cambridge, UK) software and normalized to the corresponding total ERK or β -actin levels.

Data analyses. Each experiment was performed in triplicate, and the data were expressed as mean \pm SD. Statistical analyses were performed utilizing the SPSS 11.5 software. Student's t-test and ANOVA were used in this study. Differences were considered significant when the P-values were <0.05.

Results

TAM induces cell death in MCF-7 and MCF-7/ADR cells. To explore the effect of TAM on cell death of breast cancer cells, MCF-7 or MCF-7/ADR cells were incubated in phenol red-free

RPMI-1640/1% DCC-FBS in the presence of 1, 5, 10 or 20 μ M of TAM for 1, 3, 6, 12 or 24 h. Control vehicle cells were treated with 0.1% DMSO only. As shown in Fig. 1, the number of dead MCF-7 cells increased in a time- and dose-dependent manner in the presence of TAM (Fig. 1A). Treatment with 10 μ M of TAM for 24 h resulted in a 49% of cell death in MCF-7 cells, but only ~15% of cells were dead in TAM-treated MCF-7/ADR cells (Fig. 1B). The proportion of dead cells was nearly 100% in MCF-7 cells following treatment with 20 μ M TAM (Fig. 1A); while the dead cell proportion was only 35% in MCF-7/ADR cells (Fig. 1B). These data demonstrate that MCF-7 cells are susceptible to cell death induced by TAM, with the IC_{50} of TAM in MCF-7 cells at approximately 10 μ M; while MCF-7/ADR cells are resistant to TAM.

TAM induces cell death in breast cancer cells via apoptosis. Since cell death includes necrosis and apoptosis (49), we examined whether TAM induced cell death breast cancer via an apoptotic pathway. Multiple nucleosome fragments, DNA gel electrophoresis and flow cytometry were performed in TAM-treated MCF-7 and MCF-7/ADR cells. As shown in Fig 2A, typical apoptotic bodies were observed in MCF-7 cells treated with 10 μ M of TAM for 24 h, while few apoptotic bodies appeared in the MCF-7/ADR cells. To further confirm apoptosis in these cells, genomic DNA was extracted from TAM-treated cells and was subjected to 1.5% agarose gel electrophoresis. As shown in Fig. 2B, DNA fragmentation became apparent in MCF-7 cells in response to 10 μ M of TAM exposure, with ~65% of MCF-7 cells undergoing apoptosis (Fig. 2B and C). In addition, DNA fragmentation increased in a dose-dependent manner (Fig. 2B). When cells were treated with 10 μ M TAM for 12 to 72 h, DNA ladders were visible in MCF-7 cells, and the ladders gradually increased in a time-dependent manner and peaked at 72 h (Fig. 2B). Interestingly, no DNA fragmentation was detected in TAM-treated MCF-7/ADR cells, except for the positive control cells (Fig. 2B), and the percentage of apoptotic cells in MCF-7/ADR cells was significantly lower compared to that in MCF-7 cells (Fig. 2C-D). These results suggest that TAM-induced cell death in breast cancer is predominantly due to apoptosis, and MCF-7/ADR cells are resistant to TAM.

Differential expression and phosphorylation of PKCa, PKC δ , and ERK in MCF-7 and MCF-7/ADR cells treated with




Figure 2. TAM-induced apoptosis in the MCF-7 and MCF-7/ADR cells. MCF-7 and MCF-7/ADR cells grown on 60-mm dishes (5×10^5 cells/dish) were treated with various concentrations of TAM for 24 h or with 10 mM of TAM for the indicated time periods prior to analyses as described in the Materials and methods section. (A) DAPI staining; (B) DNA fragmentation; (C) cell apoptotic histograms using flow cytometric analysis; and (D) statistical graph of cell apoptosis. M, DNA marker; ADR, MCF-7/ADR; VC, vehicle control; T5, TAM 5 μ M; T10, TAM 10 μ M; T20, TAM 20 μ M; P, positive control, where cells were treated with 5 M H_2O_2 . Data are representative of three independent experiments; * $P < 0.05$ TAM-treated cells compared to VC; # $P < 0.05$ TAM-treated MCF-7 cells compared to MCF-7/ADR cells.

TAM. To explore the possible signaling pathways involved in TAM-induced apoptosis in MCF and MCF-7/ADR cells, we investigated the expression of PKC α , PKC δ and ERK and their phosphorylation in TAM-treated cells. MCF-7 and MCF-7/ADR cells were treated with 10 μ M of TAM for 10–60 min. Our results suggested increased PKC δ and decreased PKC α expression in MCF-7 cells, while in MCF-7/ADR cells, we found decreased PKC δ and increased PKC α expression (Fig. 3A–D) ($P < 0.05$). Interestingly, TAM induced a rapid activation of PKC δ in MCF-7 cells in a time-dependent manner with the peak PKC δ activation detected at 60 min (Fig. 3C and D). Conversely, TAM stimulated PKC α phosphorylation in MCF-7 cells at 10 min, which was maintained up to 15 min. The phosphorylation level of PKC α began to decrease from 30 to 60 min, although the level of PKC α at these time points was still much higher compared to that in the vehicle control ($P < 0.05$). In MCF-7/ADR cells, the basal level of PKC α phosphorylation was high, TAM treatment did not further alter their phosphorylation (Fig. 3A and B).

To assess the relationship between the PKC and MAPK families in breast cancer cells, we investigated ERK expression and its activation. As shown in Fig. 3E and F, p-ERK1/2 started to increase 10 min following TAM exposure in MCF-7/ADR cells, and gradually increased in a time-dependent manner. However, in MCF-7 cells, ERK was only slightly activated at 30 min, with prominent phosphorylation of ERK1/2 observed at 60 min following TAM treatment. These data suggest that TAM-induced apoptosis in MCF-7 cells may be mediated through activation of PKC α , PKC δ and ERK; while the PKC α -ERK pathway promotes drug resistance in MCF-7/ADR cells.

Impact of specific inhibitors of PKC α , PKC δ and ERK on TAM-treated MCF-7 and MCF-7/ADR cells. To determine how PKC and ERK could promote both TAM-induced apoptosis and resistance, we utilized PKC and ERK inhibitors. Cells were pretreated with specific signaling inhibitors (Gö6976, 100 nM; rottlerin, 10 μ M; PD98059, 20 μ M) for 1 h and were then exposed to 10 μ M of TAM for 24 h prior to flow cytometric analyses. As shown in Fig. 4, the PKC δ inhibitor, rottlerin, clearly reduced TAM-induced apoptosis. MCF-7 cells demonstrated a $10.3 \pm 3.1\%$ reduction, and MCF-7/ADR cells showed a $5.1 \pm 2.0\%$ decrease in apoptosis ($P < 0.05$). Alternatively, we found that the PKC α/β isozyme pharmacological antagonist, Gö6976 and the MAP kinase inhibitor, PD98059 increased the rate of apoptosis in breast cancer cells. These inhibitors increased cell apoptosis by 20% and 13% in TAM-treated MCF-7 and MCF-7/ADR cells, respectively. These results suggest that PKC δ promotes TAM-induced apoptosis in MCF-7 cells, while PKC α and ERK protect breast cancer cells from death.

Effect of rottlerin and PD98059 on the expression and phosphorylation of PKC δ and ERK in TAM-treated MCF-7 cells. To investigate the relationship between PKC δ and ERK, we further assessed the impact of rottlerin and PD98059 on PKC δ and ERK activation. MCF-7 cells were pretreated with 10 μ M of rottlerin or 20 μ M of PD98059 for 1 h followed by 10 μ M of TAM for 30 or 60 min. As shown in Fig. 5, rottlerin inhibited PKC δ phosphorylation and increased activation of ERK in TAM-treated MCF-7 cells. Alternatively, PD98059 inhibited ERK activation but had no effect on PKC δ phosphorylation. These results indicate that TAM-induced apoptosis in MCF-7 cells may be mediated via activation of PKC δ and the subsequent inhibition of ERK.




Figure 3. Differential expression and phosphorylation of PKC and ERK in MCF-7 and MCF-7/ADR cells. Cells were treated with or without 10 μ M of TAM (VC, 0.1% DMSO) for various time points prior to lysis. Lysate of 60 μ g from each sample was loaded onto 12% SDS gels. P-PKC α , P-PKC δ , and P-ERK were evaluated using western blot analysis. The same membrane was re-probed using PKC α , PKC δ and ERK following stripping. (A) PKC α expression and phosphorylation; and (B) the ratio of P-PKC α to that of total PKC α ; (C) PKC δ expression and phosphorylation; and (D) the ratio of P-PKC δ to that of total PKC δ ; (E) the expression and phosphorylation of ERK; and (F) the ratio of P-ERK to that of total ERK. Data are representatives of three independent experiments (mean \pm SD). *P<0.05 TAM-treated cells compared to VC for MCF-7 cells; #P<0.05 TAM-treated compared to VC for MCF-7/ADR cells.




Figure 4. The effect of PKC and ERK inhibitors on TAM-induced apoptosis in MCF-7 and MCF-7/ADR cells. MCF-7 and MCF-7/ADR cells were pretreated with the PKC α inhibitor Gö6976 (Gö, 100 nM), the PKC δ inhibitor rottlerin (Rot, 10 μ M), or the ERK inhibitor PD98059 (PD, 20 μ M) for 1 h followed by 10 μ M of TAM (or DMSO) exposure for 24 h prior to cell collection and flow cytometry analyses. Cell apoptosis in (A) MCF-7 and (B) MCF-7/ADR. Data are mean \pm SD (n=3) representative of three independent experiments that yielded similar results. *P<0.05 compared to vehicle control; #P<0.05 significantly different from the TAM treatment alone.




Figure 5. Effect of rottlerin (Rot) or PD98059 on PKC δ and ERK activation in TAM-treated MCF-7 cells. MCF-7 cells were pretreated with or without 10 μ M of Rot or 20 μ M of PD98059 for 1 h followed by 10 μ M of TAM exposure for different time periods. A total of 60 μ g of lysates from each sample was loaded onto 12% SDS gels. P-PKC δ and P-ERK were evaluated using western blot analysis. The same membrane was re-probed for ERK following stripping. PKC δ and ERK phosphorylation and expression in MCF-7 cells after TAM treatment with or without (A and B) Rot or (C and D) PD and representation of the ratio of P-ERK to total ERK. Data are representative of three independent experiments (mean \pm SD). *P<0.05 compared to 0.1% DMSO treatment; #P<0.05 compared to TAM treatment.




Figure 6. The effect of signaling inhibitors on the expression and phosphorylation of PKC α and ERK in MCF-7/ADR cells. The MCF-7/ADR cells were pretreated with or without 100 nM of Gö6976 or 20 μ M of PD98059 for 1 h followed by 10 μ M of TAM exposure for 15 min. Lysates of 60 μ g from each sample was loaded onto 12% SDS gels. P-PKC α and P-ERK were evaluated using western blot analysis. The same membrane was re-probed for PKC α and ERK following stripping. Protein loading was assessed by stripping the membrane and re-probing with a β -actin antibody. (A) PKC α and ERK phosphorylation and the expression in MCF-7/ADR cell; (B) ERK phosphorylation rate. Data are representative of three independent experiments (mean \pm SD). *P<0.05 compared to 0.1% DMSO control; #P<0.05 compared to TAM treatment alone.

Effect of Gö6976 and PD98059 on the expression and phosphorylation of PKC α and ERK in TAM-treated MCF-7/ADR cells. As demonstrated by flow cytometry, both Gö6976 and PD98059 enhanced the TAM-induced apoptosis in MCF-7/ADR cells. We then determined how the expression and phosphorylation of PKC and ERK were regulated. We pretreated the MCF-7/ADR cells with or without 100 nM Gö6976 or 20 μ M PD98059 for 1 h followed by 10 μ M TAM exposure for 15 min. As shown in Fig. 6, both Gö6976 and PD98059 inhibited TAM-induced ERK phosphorylation in MCF-7/ADR cells; however, PD98059 had no effect on PKC α activity. We therefore, hypothesize that ERK may act downstream of PKC α , cooperating together on TAM resistance in MCF-7/ADR cells.

Discussion

Growing evidence on the mechanism of TAM-induced cancer inhibition have led to the discovery of many signaling intermediates that may play critical roles in this process (50). However, mechanisms underlying TAM-induced apoptosis and TAM resistance are still not completely understood. In the present study, we determined for the first time that TAM was involved in both apoptotic and anti-apoptotic signaling pathways in breast cancer cells. We found that PKC δ phosphorylation participated in TAM-induced apoptosis in MCF-7 cells by antagonizing downstream ERK signaling; while in MCF-7/ADR cells, PKC α activated downstream ERK signaling

and promoted drug resistance. Our results also revealed that Gö6976 and PD98059 could promote TAM-induced apoptosis in these cells.

In breast cancer, TAM results in either a cytostatic end point (cell growth arrest) at nanomolar (nM) or a cytotoxic end point (cell death leading to tumor shrinkage and regression *in vivo*) at micromolar (μ M) concentrations (41). We observed that TAM-induced cell death in MCF-7 cells was dose- and time-dependent. However, in MCF-7/ADR cells, even with high concentrations and long term exposure of TAM (10 μ M, for 72 h), the rate of apoptosis was still very low, implying that MCF-7/ADR cells were resistant to TAM.

There are many contradictory data on the pro-apoptotic or pro-survival effects of PKC δ (16,22,25). PKC δ has been reported to protect RAW264.7 macrophages from nitric oxide-induced apoptosis (51). PKC δ increased mammary tumor cell growth and metastasis by activation of the Ras/ERK1/2 pathway (27). In this study, TAM stimulated PKC δ activation in MCF-7 cells. The PKC δ specific inhibitor, rottlerin, prevented TAM-induced apoptosis by inhibiting PKC δ phosphorylation and elevating p-ERK; while the ERK inhibitor, PD98059 increased apoptosis, but had no effect on PKC δ activation in these cells, indicating that ERK is the downstream mediator of PKC δ . Our results are different from a report by Greco *et al* (52) in which they suggest that PKC δ/ϵ mediated the PKC/Akt-dependent phosphorylation of ERK in MCF-7 cells, and led to cell proliferation. It is therefore possible that the activation of PKC δ by various factors may lead to divergent signaling pathways.

PKC α is associated with cell proliferation in various cell types (53-55). Several lines of evidence indicate that inhibition of PKC α is sufficient to induce apoptosis, suggesting that PKC α functions to suppress apoptosis in some cells (56,57). Overexpression of PKC α has been reported to promote the progression of breast cancer and reduce the expression of ER in MCF-7 cells (58). Interestingly, we observed that p-PKC α was overexpressed in the ER-negative MCF-7/ADR cells; it is possible that the high level of endogenous PKC α in MCF-7/ADR cells contributes to TAM resistance. In the present study, we also found that TAM promoted ERK activation in MCF-7/ADR cells, and both Gö6976 and PD98059 enhanced TAM-induced apoptosis by inhibiting ERK phosphorylation, however, these inhibitors did not alter PKC α activation, indicating that ERK was the downstream mediator of PKC α and participated in the drug resistance of MCF-7/ADR cells. These results are in accordance with a previous study suggesting that PKC counteracts apoptosis by acting on downstream effectors (the MAPK pathway) in Jurkat T cells (59,60). Lin *et al* (61) also found that MAPK activation promoted β -estradiol-induced breast carcinoma cell proliferation. Conversely, Fujii *et al* (25) reported that the antineoplaston A10 arrested SKBR-3 cells in the G1 phase via PKC α and MAPK; and Wu and Huang (62) reported that PKC α is specifically required for TPA-induced ERK (MAPK) signaling, leading to inhibition of HepG2 cell growth.

In summary, our present results suggest that the PKC-ERK pathway plays an important role in mediating TAM-induced apoptosis as well as TAM resistance in breast cancer cells. PKC δ phosphorylation promoted TAM-induced apoptosis in MCF-7 cells by antagonizing ERK activation, while PKC α was involved in TAM resistance by activating downstream

ERK signaling in MCF-7/ADR cells. Therefore, combinations of TAM with Gö6976 and PD98059 could promote TAM-induced apoptosis in breast cancer cells and reduce TAM resistance.

Acknowledgements

This study was supported by grants from the CMB (98-677 to F.X.) and the National Nature Science Foundation of China (30570762 to C. Li). We thank Dr Qingyu Kong for technical support in fluorescence activated cell-sorting and Professor Guoquan Gao for providing the Gene Genius Bio-imaging System to analyze our western blotting results. We also thank the Medjaden Bioscience Limited for assisting in the preparation of this manuscript.

References

1. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD and Murray CJ: Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. *BMC Cancer* 26: 37, 2002.
2. Gerl R and Vaux DL: Apoptosis in the development and treatment of cancer. *Carcinogenesis* 26: 263-270, 2005.
3. Tian F, Wu H, Li Z, Wang N, Huang J, Li C and Xie F: Activated PKC α /ERK1/2 signaling inhibits tamoxifen-induced apoptosis in C6 cells. *Cancer Invest* 27: 802-808, 2009.
4. Todorova VK, Kaufmann Y, Luo S and Klimberg VS: Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake. *Cancer Chemother Pharmacol* 67: 285-291, 2011.
5. Lazarus P, Blevins-Primeau AS, Zheng Y and Sun D: Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen. *Ann NY Acad Sci* 1155: 99-111, 2009.
6. McDonnell DP and Norris JD: Connections and regulation of the human estrogen receptor. *Science* 296: 1642-1644, 2002.
7. Jordan VC: Selective estrogen receptor modulation: concept and consequences in cancer. *Cancer Cell* 5: 207-213, 2004.
8. Howell A, Bundred NJ, Cuzick J, Allred DC and Clarke R: Response and resistance to the endocrine prevention of breast cancer. *Adv Exp Med Biol* 617: 201-211, 2008.
9. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H and Schiff R: Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. *J Natl Cancer Inst* 96: 926-935, 2004.
10. Clemens MJ, Trayner I and Menaya J: The role of protein kinase C isoenzymes in the regulation of cell proliferation and differentiation. *J Cell Sci* 103: 881-887, 1992.
11. Hug H and Sarre TF: Protein kinase C isoenzymes: divergence in signal transduction? *Biochem J* 291: 329-343, 2005.
12. Tanaka Y, Gavrielides MV, Mitsuchi Y, Fujii T and Kazanietz MG: Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the akt survival pathway. *J Biol Chem* 278: 33753-33762, 2003.
13. Newton AC: Protein kinase C: structure, function, and regulation. *J Biol Chem* 270: 28495-28498, 1995.
14. Way KJ, Chou E and King GL: Identification of PKC-isoform-specific biological actions using pharmacological approaches. *Trends Pharmacol Sci* 21: 181-187, 2000.
15. Morse-Gaudio M, Connolly JM and Rose DP: Protein kinase C and its isoforms in human breast cancer cells: Relationship to the invasive phenotype. *Int J Oncol* 12: 1349-1354, 1998.
16. Soh JW, Lee YS and Weinstein IB: Effects of regulatory domains of specific isoforms of protein kinase C on growth control and apoptosis in MCF-7 breast cancer cells. *J Exp Ther Oncol* 3: 115-126, 2003.
17. Frankel LB, Lykkesfeldt AE, Hansen JB and Stenvang J: Protein Kinase C α is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells. *Breast Cancer Res Treat* 104: 165-179, 2007.
18. Tonetti DA, Chisamore MJ, Grdina W, Schurz H and Jordan VC: Stable transfection of protein kinase C α cDNA in hormone-dependent breast cancer cell lines. *Br J Cancer* 83: 782-791, 2000.

19. Blobe GC, Sachs CW, Khan WA, Fabbro D, Stabel S, Wetsel WC, Obeid LM, Fine RL and Hannun YA: Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. *J Biol Chem* 268: 658-664, 1993.
20. Shanmugam M, Krett NL, Maizels ET, Cutler RE Jr, Peters CA, Smith LM, O'Brien ML, Park-Sarge OK, Rosen ST and Hunzicker-Dunn M: Regulation of protein kinase C delta by estrogen in the MCF-7 human breast cancer cell line. *Mol Cell Endocrinol* 148: 109-118, 1999.
21. Kruger JS and Reddy KB: Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells. *Mol Cancer Res* 1: 801-809, 2003.
22. McCracken MA, Miraglia LJ, McKay RA and Strobl JS: Protein kinase C delta is a prosurvival factor in human breast tumor cell lines. *Mol Cancer Ther* 2: 273-281, 2003.
23. Grossoni VC, Falbo KB, Kazanietz MG, de Kier Joffé ED and Urtreger AJ: Protein kinase C delta enhances proliferation and survival of murine mammary cells. *Mol Carcinog* 46: 381-390, 2007.
24. Maizels ET, Shanmugam M, Lamm ML and Hunzicker-Dunn M: Hormonal regulation of PKC-delta protein and mRNA levels in the rabbit corpus luteum. *Mol Cell Endocrinol* 122: 213-221, 1996.
25. Fujii T, Nakamura AM, Yokoyama G, Yamaguchi M, Tayama K, Miwa K, Toh U, Kawamura D, Shirouzu K, Yamana H, *et al*: Antineoplastic induction G (1) arrest by PKC α and MAPK pathway in SKBR-3 breast cancer cells. *Oncol Rep* 14: 489-494, 2005.
26. Liu JF, Crépin M, Liu JM, Barritault D and Ledoux D: FGF-2 and TPA induce matrix metalloproteinase-9 secretion in MCF-7 cells through PKC activation of the Ras/ERK pathway. *Biochem Biophys Res Commun* 293: 1174-1182, 2002.
27. Keshamouni VG, Mattingly RR and Reddy KB: Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-delta. *J Biol Chem* 277: 22558-22565, 2002.
28. Clark AS, West KA, Blumberg PM and Dennis PA: Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. *Cancer Res* 63: 780-786, 2003.
29. Zarubin T and Han J: Activation and signaling of the p38MAP kinase pathway. *Cell Res* 15: 11-18, 2005.
30. Reddy KB, Krueger JS, Kondapaka SB and Diglio CA: Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells. *Int J Cancer* 82: 268-273, 1999.
31. Frost JA, Geppert TD, Cobb MH and Feramisco JR: A requirement for extracellular signal-regulated kinase (ERK) function in the activation of AP-1 by Ha-Ras, phorbol 12-myristate 13-acetate, and serum. *Proc Natl Acad Sci USA* 91: 3844-3848, 1994.
32. Pagès G, Lenormand P, L'Allemand G, Chambard JC, Meloche S and Pouyssegur J: Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. *Proc Natl Acad Sci USA* 90: 8319-8323, 1993.
33. Zhang W and Liu H: MAPK signal pathways in the regulation of cell proliferation in mammalian cells. *Cell Res* 12: 9-18, 2002.
34. Lei X, Yang J, Nichols RW and Sun LZ: Abrogation of TGF β signaling induces apoptosis through the modulation of MAP kinase pathways in breast cancer cells. *Exp Cell Res* 313: 1687-1695, 2007.
35. Peyssonnaud C and Eychène A: The Raf/MEK/ERK pathway: new concepts of activation. *Biol Cell* 93: 53-62, 2001.
36. Yan Y, Haas JP, Kim M, Sgagias MK and Cowan KH: BRCA1-induced apoptosis involves inactivation of ERK1/2 activities. *J Biol Chem* 277: 33422-33430, 2002.
37. Duh JL, Yu R, Jiao JJ, Matwysyn GA, Li W, Tan TH and Kong AN: Activation of signal transduction kinases by tamoxifen. *Pharm Res* 14: 186-189, 1997.
38. Acconcia F and Kumar R: Signaling regulation of genomic and nongenomic functions of estrogen receptors. *Cancer Lett* 238: 1-14, 2006.
39. Zheng A, Kallio A and Härkönen P: Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogen. *Endocrinology* 148: 2764-2777, 2007.
40. Katayama K, Yoshioka S, Tsukahara S, Mitsuhashi J and Sugimoto Y: Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. *Mol Cancer Ther* 6: 2092-2102, 2007.
41. Mandlekar S and Kong AN: Mechanisms of tamoxifen-induced apoptosis. *Apoptosis* 6: 469-477, 2001.
42. Lamb JA, Ventura JJ, Hess P, Flavell RA and Davis RJ: Jun D mediates survival signaling by the JNK signal transduction pathway. *Mol Cell* 11: 1479-1489, 2003.
43. Park SK, Sanders BG and Kline K: Tocotrienols induce apoptosis in breast cancer cell lines via an endoplasmic reticulum stress-dependent increase in extrinsic death receptor signaling. *Breast Cancer Res Treat* 124: 361-375, 2010.
44. Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. *Science* 270: 1326-1331, 1995.
45. Schafer JM, Bentrem DJ, Takei H, Gajdos C, Badve S and Jordan VC: A mechanism of drug resistance to tamoxifen in breast cancer. *J Steroid Biochem Mol Biol* 83: 75-83, 2002.
46. Migliaccio A, Pagano M and Auricchio F: Immediate and transient stimulation of protein tyrosine phosphorylation by estradiol in MCF-7 cells. *Oncogene* 8: 2183-2191, 1993.
47. Dong YG, Chen DD, He GJ and Guan YY: Effects of 15-deoxy-delta12, 14-prostaglandin J2 on cell proliferation and apoptosis in ECV304 endothelial cells. *Acta Pharmacol Sin* 25: 47-53, 2004.
48. Li C, Hu Y, Mayr M and Xu Q: Cyclic strain stress-induced mitogen-activated protein kinase (MAPK) phosphatase 1 expression in vascular smooth muscle cells is regulated by Ras/Rac-MAPK pathways. *J Biol Chem* 274: 25273-25280, 1999.
49. Buytaert E, Dewaele M and Agostinis P: Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. *Biochim Biophys Acta* 1776: 86-107, 2007.
50. Vessièrès A, Corbet C, Heldt JM, Lories N, Jouy N, Laios I, Leclercq G, Jaouen G and Toillon RA: A ferrocenyl derivative of hydroxytamoxifen elicits an estrogen receptor-independent mechanism of action in breast cancer cell lines. *J Inorg Biochem* 104: 503-511, 2010.
51. Jun CD, Oh CD, Kwak HJ, Pae HO, Yoo JC, Choi BM, Chun JS, Park RK and Chung HT: Over-expression of protein kinase C isoforms protects RAW264.7 macrophages from nitric oxide-induced apoptosis: involvement of c-Jun N-terminal kinase/stress-activated protein kinase, p38 kinase, and CPP-32 protease pathways. *J Immunol* 162: 3395-3401, 1999.
52. Greco S, Storelli C and Marsigliante S: Protein kinase C (PKC) δ/ϵ mediate the PKC/Akt-dependent phosphorylation of extracellular signal-regulated kinases 1 and 2 in MCF-7 cells stimulated by bradykinin. *J Endocrinol* 188: 79-89, 2006.
53. Mandil R, Ashkenazi E, Blass M, Kronfeld I, Kazimirsky G, Rosenthal G, Umansky F, Lorenzo PS, Blumberg PM and Brodie C: Protein kinase C α and protein kinase C δ play opposite roles in the proliferation and apoptosis of glioma cells. *Cancer Res* 61: 4612-4619, 2001.
54. Capiati DA, Vazquez G, Tellez Iñón MT and Boland RL: Antisense oligonucleotides targeted against protein kinase C α inhibit proliferation of cultured avian myoblasts. *Cell Prolif* 33: 307-315, 2000.
55. Bollag WB: Protein kinase C α puts the hand cuffs on epidermal keratinocyte proliferation. *J Invest Dermatol* 129: 2330-2332, 2009.
56. Matassa AA, Kalkofen RL, Carpenter L, Biden TJ and Reyland ME: Inhibition of PKC α induces a PKC δ -dependent apoptotic program in salivary epithelial cells. *Cell Death Differ* 10: 269-277, 2003.
57. Wang WL, Yeh SF, Huang EY, Lu YL, Wang CF, Huang CY and Lin WJ: Mitochondrial anchoring of PKC α by PICK1 confers resistance to etoposide-induced apoptosis. *Apoptosis* 12: 1857-1871, 2007.
58. Ways DK, Kukoly CA, deVente J, Hooker JL, Bryant WO, Posekany KJ, Fletcher DJ, Cook PP and Parker PJ: MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. *J Clin Invest* 95: 1906-1915, 1995.
59. Ruiz-Ruiz C, Robledo G, Font J, Izquierdo M and López-Rivas A: Protein kinase C inhibits CD95 (Fas/APO-1)-mediated apoptosis by at least two different mechanisms in Jurkat T cells. *J Immunol* 163: 4737-4746, 1999.
60. Whitehurst CE, Boulton TG, Cobb MH and Geppert TD: Extracellular signal regulated kinases in T cells. Anti-CD3 and 4 beta-phorbol 12-myristate 13- acetate-induced phosphorylation and activation. *J Immunol* 148: 3230-3237, 1992.
61. Lin CW, Yang LY, Shen SC and Chen YC : IGF-I plus E2 induces proliferation via activation of ROS-dependent ERKs and JNKs in human breast carcinoma cells. *J Cell Physiol* 212: 666-674, 2007.
62. Wu WS and Huang JM: Activation of protein kinase C alpha is required for TPA-triggered ERK (MAPK) signaling and growth inhibition of human hepatoma cell HepG2. *J Biomed Sci* 12: 289-296, 2005.